Lee Silverman Voice Treatment for dysarthria in patients with Parkinson's disease: a systematic review and meta‐analysis. (12th August 2020)

• Record Type: Journal Article
• Authors: Yuan, F.; Guo, X.; Wei, X.; Xie, F.; Zheng, J.; Huang, Y.; Huang, Z.; Chang, Z.; Li, H.; Guo, Y.; Chen, J.; Guo, J.; Tang, B.; Deng, B.; Wang, Q.
• Is Part Of: European journal of neurology. Volume 27:Number 10(2020)
• Page Start: 1957
• Page End: 1970
• Publication Date: 2020-08-12
• Subjects: Lee Silverman Voice Treatment -- meta‐analysis -- Parkinson's disease -- randomized controlled trials -- speech intervention -- systematic review; Neurology -- Periodicals; Nervous system -- Diseases -- Periodicals; 616.8
• DOI: 10.1111/ene.14399
• Languages: English
• ISSNs: 1351-5101

Abstract

Abstract : Approximately 89% of patients with Parkinson's disease (PD) suffer from dysarthria. Lee Silverman Voice Treatment (LSVT), a behavioral therapy, aims to improve speech and voice functions. The objective was to assess the effectiveness of LSVT compared with other/no speech interventions for dysarthria in patients with PD. Electronic databases, including PubMed, Embase and the Cochrane Library, were searched. The publication date of all included studies was before 6 March 2020. Only randomized controlled trials (RCTs) that evaluated the LSVT intervention compared with other/no speech intervention were considered. The data obtained from the included studies were described and the mean differences were calculated. Eight RCTs were included in this meta‐analysis comparing LSVT with other/no speech interventions. In the comparison of LSVT versus no intervention, vocal intensity for sustained 'Ah' phonation, reading the 'Rainbow passage', monologue and describing a picture increased by 8.87, 4.34, 3.25 and 3.31 dB, respectively, after 1 month of therapy. Compared with the respiratory therapy group, the LSVT group also showed significant improvement in vocal intensity for sustained 'Ah' phonation, reading the 'Rainbow passage' and monologue immediately after treatment (13.39, 6.66 and 3.19 dB). Positive improvement still existed after 24 months. There was no difference in the therapeutic effect between face‐to‐face and online LSVT. The effectiveness of LSVT for dysarthria in patients with PD was verified in these trials. However, future RCTs with sufficient participants are essential to evaluate the effectiveness of LSVT for dysarthria.